JPRN-UMIN000004686CompletedPhase 2
A phase II study of Carboplatin+Pemetrexed +Bevacizumab for gefitinib refractory NSCLC patients with mutated EGFR - A phase II study of Carboplatin+Pemetrexed +Bevacizumab for gefitinib refractory NSCLC patients with mutated EGFR
iigata Lung Cancer Treatment Group0 sites35 target enrollmentStarted: December 8, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 35
Study Overview
Brief Summary
A
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Radiation therapy to primary cancer 2.Active infection or other serious conditions 3. Severe pleural effusion or uncontrollable pleural effusion 4.Symptomatic brain metastasis 5. Uncontrollable hypertension 6. Uncontrollable diabetes mellitus 7. Current or previous history of hemoptysis or hemosputum 8. Current or previous (within the last 1 year) history of GI perforation 9. Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 10.Tumor invasive to the chest large blood vessel. 11.Evidence of bleeding diathesis or coagulopathy 12.History of active double cancer 13.History of active psychological disease 14.History of pregnancy or lactation 15. Active concomitant malignancy 16. Active mental illness 17. Previous treatment with Carboplatin or Pemetrexed or Bevacizumab 18. History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris etc)
Investigators
Similar Trials
Completed
Not Applicable
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)Advanced non-squamous non-small cell lung cancer with EGFR MutationJPRN-UMIN000003737Central Japan Lung Study Group32
Completed
Phase 2
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer without EGFR Mutation (CJLSG0909)Advanced non-squamous non-small cell lung cancer without EGFR MutationJPRN-UMIN000003736Central Japan Lung Study Group52
Completed
Phase 2
Phase II Study of Carboplatin+Pemetrexed+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC).non-squamous non-small cell lung cancerJPRN-UMIN000003387Kansai Medical University Hirakata Hospital25
Completed
Not Applicable
Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A)on-small cell lung cancer (non-squamous cell carcinoma)JPRN-UMIN000006243orth-East Japan study group30
Completed
Phase 2
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26